Eric Pujade-Lauraine, MD, PhD | Authors


Exploratory Analyses for JAVELIN Ovarian 200 Demonstrate Potential for Immunotherapy in Select Subgroups

June 12, 2019

Eric Pujade-Lauraine, MD, PhD, discusses the exploratory findings from the phase III JAVELIN Ovarian 200 trial, which investigated the use of combination avelumab plus pegylated liposomal doxorubicin in patients with platinum-resistant, refractory ovarian cancer.